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Abstract 
Purpose: To determine the prevalence of drusen-like deposits (DLDs) and choroidal 
changes in patients with Systemic Lupus Erythematosus (SLE), with or without 
glomerulonephritis. To correlate ocular findings with systemic features. 
Design: Case-control study 
Methods: Sixty patients with SLE (18-55 years; 30 with and 30 without SLE-related 
glomerulonephritis) and 60 age and gender matched healthy controls were enrolled. All 
patients underwent non-invasive, multimodal imaging that included fundus photography, 
near-infrared reflectance, blue autofluorescence, blue reflectance, and spectral-domain 
optical coherence tomography (SD-OCT). Images were analyzed for the prevalence of 
DLDs. Distribution, size, and number of DLDs were measured. Correlations between 
ocular findings and systemic features were analyzed. Subfoveal choroidal thickness 
(SCT) was measured using the SD-OCT. 
Results: Drusen-like deposits were detected in 40% of SLE subjects and 3.33% of 
controls (P<0.0001). Compared to other techniques, SD-OCT detected the largest 
number of affected subjects. In eyes with DLDs, small, medium, and large lesions were 
found in 75%, 50%, and 42% of cases, respectively. Drusen-like deposits were located 
in the nasal, temporal, inferior, superior, and central regions of the posterior pole in 
83%, 75%, 67%, 54%, and 25% eyes, respectively. The prevalence of DLDs in patients 
with SLE were similar regardless of renal involvement, but patients with 
glomerulonephritis had more DLDs/eye, larger deposits, and DLDs in >3 quadrants 
(P<0.001, P=0.03, P=0.009, respectively). Subfoveal choroidal thickness was greater in 
patients with SLE (P=0.002). 
Conclusions: Drusen-like deposits in patients with SLE were independent of renal 
disease and were best detected with SD-OCT. Lupus-related glomerulonephritis was 
associated with more fundus abnormalities and a screening SD-OCT should be 
considered in all patients with SLE. Drusen like deposits in the absence of 
glomerulonephritis may support the recent proposal that complement alteration is the 
primary cause for these lesions. 
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Introduction  
Systemic Lupus Erythematosus (SLE) is an autoimmune disease 
characterized by loss of immune tolerance against nuclear antigens, 
polyclonal autoantibody production, immune complex deposition, multi-organ 
damage, and a relapsing/remitting clinical course.1 As with most autoimmune 
diseases, there are no specific clinical or laboratory tests to confirm the 
diagnosis of SLE. Instead, the diagnosis of SLE is based on the presence of 
at least 4 of the 11 criteria described by the American Rheumatologists 
Association (ARA).2 The ARA criteria consist of a number of SLE-related 
organ disorders such as skin rash, arthritis, nephritis and immune dysfunction. 
 
Although not mentioned in the ARA list, ophthalmologic involvement can 
occur in 2% to 30% of patients with SLE. Several ocular tissues can be 
involved, but the retinal vessels are most commonly affected.3 Early 
manifestations of retinopathy, such as small intraretinal hemorrhages and 
cotton wool spots, usually occur prior to the onset of ocular symptoms.4 
Detecting these abnormalities on fundus examination can identify patients at 
high risk for more advanced disease.5  
 
A number of asymptomatic funduscopic changes have been reported to be 
possible markers for disease activity. Baglio et al. found choroidal alterations 
and drusen-like deposits (DLDs) on indocyanine green angiography (ICGA) in 
a small cohort of patients affected by SLE glomerulonephritis. They suggested 
a possible correlation between these ocular findings and renal involvement.6 
The absence of large confirmatory studies, and the invasive nature and high 
costs of ICGA may contribute to the rarity of these findings. 
 
During the past few years, non-invasive imaging techniques, particularly 
fundus autofluorescence (FAF) and spectral domain optical coherence 
tomography (SD-OCT), have become the gold standards for the detection and 
characterization of drusen and DLDs both in ocular and systemic conditions.7-
10 The introduction of enhanced-depth imaging (EDI) has improved 
visualization of the choroid on SD-OCT and enables non-invasive assessment 
of choroidal structures and measurement of thickness in several diseases 
including SLE.11 
 
The aim of this index study was to assess the prevalence of DLDs and 
choroidal changes in patients with SLE (with or without renal involvement) 
using various non-invasive imaging techniques, and to compare them to age 
and gender-matched healthy controls. Correlation between the ocular findings 
and the systemic status of the patients, including the ARA criteria, treatment, 
and the renal involvement, was also determined. 
 
Methods 
 
In this cross-section, case-control study, sixty patients with SLE that were 
being treated in the Immunology/Nephrology Unit of the IRCCS-Cà Granda 
Foundation – Ospedale Maggiore Policlinico, Milan, Italy, and sixty age and 
gender-matched healthy controls were enrolled. Institutional Review Board 
approval was obtained and the study adhered to the tenets of the Declaration 
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of Helsinki. Written informed consent was obtained from all the subjects prior 
to enrollment in the study. 
 
Inclusion Criteria 
 
The diagnosis of SLE was based on the presence of at least 4 of the 11 ARA 
criteria. Among the 60 patients with SLE (cases), 30 had biopsy-proven, SLE-
related glomerulonephritis and the remaining 30 had SLE without renal 
involvement. The American College of Rheumatology (ACR) criteria for 
glomerulonephritis - detection of persistent proteinuria >0.5 gm/day or > 3+ by 
dipstick, and/or cellular casts including red cells, hemoglobin, granular, tubular 
or mixed12 - were used to rule out renal disease. 
 
Patients with refractive errors less than spherical equivalent of ±3 diopters 
were included in the study. Age-matched control subjects had no known 
ocular or systemic diseases. 
 
Exclusion Criteria 
 
Patients with one or more of the following conditions were excluded: history of 
previous or ongoing ocular or systemic disease known to cause changes in 
the retina or the choroid other than SLE; history of previously diagnosed SLE-
related retinopathy (i.e. small intraretinal hemorrhages and cotton wool spots); 
media opacities that prevent the acquisition of images that are adequate for 
analysis; and inability to understand or sign the informed consent. Patients 
older than 55 years were excluded to avoid the presence of age-related 
drusen. 
 
Study Procedures 
 
All patients enrolled into the study underwent complete ocular examinations, 
including best correct visual acuity (BCVA), anterior segment slit lamp 
examination, applanation Goldmann tonometry, and a slit lamp funduscopic 
exam. Non-invasive, multi-imaging studies of the fundus, including color 
fundus photography (FP) (Canon CR1 Mark II, Canon Inc., Tokyo, Japan), 
near infrared reflectance (NIR), blue autofluorescence (BAF), blue reflectance 
(BR), and SD-OCT (Heidelberg Spectralis®, Heidelberg 
Engineering, Heidelberg, Germany) were performed in both eyes. Near 
infrared reflectance, BAF, and BR images of the 30 central degrees of the 
retina with a mean ART® of 100 frames were obtained after adequate pupillary 
dilation (tropicamide 1%). The SD-OCT scan pattern consisted of a dense 
volume (30 × 25º) with a mean ART® of 25 frames, 2 single line scans 
(horizontal and vertical) with a mean ART® of 100 frames passing through the 
fovea, and EDI. 
 
Image Analyses 
 
One eye of each patient was randomly selected for further analysis. Image 
analyses were divided into two consecutive steps. In the first part of the 
analyses, the prevalence of DLDs were determined to establish which 
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imaging modality had the highest detection sensitivity. The complete set of 
images from each eye was independently analyzed by two trained graders 
(A.I. and L.dA.). In cases of disagreement between the two graders, a third 
grader (F.V.) was asked to adjudicate. When ≥1 DLDs were detected by at 
least one imaging modality, the subject was considered to be positive for the 
presence of DLDs and was selected for further analysis. When DLDs were 
detected in one eye, the contralateral eye was evaluated to determine 
bilateral involvement. 
  
For each imaging modality, the detection sensitivity for DLDs was calculated 
by considering multimodal imaging as the gold standard (i.e. the number of 
patients positive for DLDs by each technique was compared to the total 
number of patients positive for DLDs by multimodal imaging).  
 
Since SD-OCT was the most sensitive technique for detecting DLDs, the 
second part of the analysis was performed to characterize DLDs on SD-OCT. 
The scanned area of the posterior pole was divided into 5 smaller areas of 
interest, superior, temporal, inferior, and nasal zones that were bounded by 
the intermediate and external rings of the ETDRS grid, and a central zone 
within the inner ETDRS ring. Each B-scan of the SD-OCT was analyzed to 
assess the size, location, and number of DLDs. Drusen like deposits were 
classified into 3 different categories according to their size: small (<50 µm); 
medium (from 50 to 100 µm); and large (≥100 µm). The lesion size was 
determined with the embedded caliper function by drawing a single line 
segment parallel to the Bruch’s membrane that passed within the elevation of 
the retinal pigment epithelium (Figure 1). 
 
Subfoveal choroidal thickness was measured with the embedded caliper 
function by drawing a vertical line segment on the vertical and horizontal EDI-
OCT scans through the fovea and calculating a mean value. Two independent 
graders each measured the subfoveal choroidal thickness twice. 
 
Statistical Analysis 
 
Sensitivities of the different imaging techniques were determined to identify 
the most suitable technique to detect and characterize DLDs. The Chi Square 
test was used to compare the prevalence of DLDs in cases and controls. 
Fisher’s Exact test was used to compare patients affected by SLE-related 
glomerulonephritis and patients without glomerulonephritis for the presence of 
DLDs, regardless of their size. In eyes where alterations were identified, 
descriptive statistics were used to represent the distribution of the lesions in 
the different areas of the posterior pole. Fisher’s Exact test was also used to 
determine whether the number of posterior pole quadrants affected by DLDs 
and the prevalence of small, medium and large DLDs differed between 
patients with and without glomerulonephritis.  
 
Given the non-normal distribution of DLDs in the studied population and the 
small sample size, a Kolmogorov-Smirnov non-parametric test was used to 
compare the absolute number of DLDs found in eyes from patients with and 
without glomerulonephritis. A Generalized Linear model (GLM) was used to 
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correlate the presence of DLDs with systemic features of the patients with 
SLE, including 
ARA criteria, complement C3 and C4 depletion (detected at least once in the 
patient’s clinical history), age of disease onset, and disease duration. The 
Intra-class Correlation Coefficient (ICC) was used to assess inter-observer 
agreement of choroidal measurements. The Student’s t-test was used to 
compare subfoveal choroidal thickness. 
 
Results 
 
The mean age of the patients was 42 ± 9 years (range: 19 – 55 years) and 
59/60 patients were females. Detailed clinical histories of the patients, 
including the prevalence of ARA criteria, age of disease onset, duration of 
disease, C3/C4 levels, and the ongoing treatment at the time of the study are 
reported in Table 1. 
 
Drusen like deposits were detected by multimodal imaging in 40% (24/60) of 
patients with SLE and in 3.33% (2/60) of healthy controls (P<0.0001). In 
patients with DLDs, 70.83% (17/24) of them had bilateral involvement, 
resulting in bilateral DLDs in 28.33% (17/60) of the entire SLE cohort. None of 
the controls had bilateral DLDs (P=0.0001). A detailed comparison of ocular 
findings between cases and controls is reported in Table 2. 
 
The graders were able to detect DLDs with SD-OCT in all the affected 
patients (100% sensitivity; 24/24 eyes). The sensitivity of the other imaging 
techniques was lower: NIR, 62% (15/24); FAF, 46% (11/24); FP, 46% (11/24), 
and BR, 21% (5/24). Multimodal imaging sets from a representative patient 
with DLDs is shown in Figure 2. On SD-OCT, small DLDs were the most 
common alteration in patients with SLE (75%; 18/24). Medium DLDs were 
present in 50% (12/24) of patients and large DLDs were found in 42% (10/24).  
 
All DLDs were located between the retinal pigment epithelium (RPE) and 
Bruch’s membrane. Their appearance ranged from hypo-reflective dots that 
wrinkled the overlying RPE (small lesions), to distinct hypo-reflective dome-
shaped lesions that detached the RPE from the underlying Bruch’s membrane 
(large lesions) (Figure 3). 
 
Drusen like deposits were variably distributed throughout the posterior pole. 
Nasal and temporal quadrants were the most commonly involved areas (83% 
(20/24) and 75% (18/24) of the patients with DLDs, respectively); inferior and 
superior areas were affected in 67% (16/24) and 54% (13/24), respectively. 
Central macular involvement was found in 25% of patients (6/24) (Figure 4). 
Similar numbers of patients with and without glomerulonephritis had DLDs 
(40% (12/30) of eyes in both groups). The total number of DLDs per affected 
eye, however, was significantly higher in patients with renal disease 
(P=0.001). Among patients with SLE-related glomerulonephritis, DLDs were 
more widely distributed (involving more than 3 posterior pole quadrants) 
compared to SLE patients without renal disease (P=0.009). No significant 
differences in the prevalence of small or medium DLDs were observed when 
comparing SLE patients with and without renal involvement. The number of 
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subjects with large DLDs, however, was significantly higher in patients with 
glomerulonephritis (P=0.03). Ocular findings among SLE patients with and 
without renal involvement are compared in Table 3. 
 
Good agreement regarding the measurement of subfoveal choroidal thickness 
(ICC=0.92) was seen between the two graders. The mean subfoveal 
choroidal thickness (SCT) was significantly greater in patients with SLE (362.7 
± 142.2 µm) compared to controls (296.5 ± 83.4 µm) (P=0.002). No significant 
differences were found between the choroidal thickness of SLE patients with 
or without glomerulonephritis (Table 2 and 3). No significant differences were 
found in the SCT of SLE patients treated with systemic corticosteroids at the 
time of the study (355 ± 147.6 µm) compared to those not receiving steroids 
(383.9 ± 128.1 µm; P=0.49). Five percent of patients affected by SLE (3/60) 
showed signs of a chronic retinal pigment epitheliopathy (small serous RPE 
detachments, shallow subretinal fluid pockets), but none were seen in 
controls. No significant correlations were found between the presence of 
DLDs and any of the ARA criteria, C3-C4 depletion, disease duration, age of 
onset, and method of treatment (all P>0.05). 
 
 
Discussion 
 
Non-invasive multimodal imaging of the fundus demonstrated the presence of 
DLDs in a significantly higher percentage of young adults affected by SLE 
compared to healthy controls. These had been previously identified with 
fluorescein and ICG angiography in a small group of patients affected by SLE-
related glomerulonephritis6 but not in patients who did not have 
glomerulonephritis. The authors concluded that DLDs occur only in SLE 
patients with kidney disease and may be a sign of renal involvement.  
 
To the best of our knowledge, ours represents the first report of DLDs in 
young SLE patients without kidney involvement. According to the results of 
our study, patients without renal disease that had been previously reported to 
show no ocular alterations,6 are actually affected by smaller and less 
numerous DLDs compared to the patients with renal involvement. Newer 
imaging techniques with higher resolutions than FA and ICGA are able to 
detect these microscopic alterations. Detailed tomographic scanning of each 
retinal layer with SD-OCT enables identification of RPE alterations that could 
not be detected previously (Figure 5). This is consistent with previous reports 
in the literature.13 The presence of DLDs in patients with glomerulonephritis, 
either related to SLE6 or another etiology,10,14 is thought to be related to the 
anatomical similarities between the glomerulus and the 
choriocapillaris/Bruch’s membrane/retinal pigment epithelium complex.15 
 
Detection of DLDs in similar proportions of patients with and without nephritis, 
however, calls for a more detailed explanation. Several histopathological 
investigations have demonstrated the presence of complement components in 
age-related drusen as well as in glomerulonephritis-associated DLDs.16-18 The 
same authors suggest a possible role of complement activation/deposition or 
complement pathway abnormalities in the formation of drusen and DLDs. 
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Since complement activation and depletion is a hallmark of SLE disease, 
even in the absence of clinically detectable renal involvement, complement 
factors could play a major role in the development of DLDs in SLE patients. 
Low CH50 and C3 levels have been associated with histopathologically 
proven, but clinically undetectable, glomerulonephritis in patients with SLE, an 
entity called Silent Lupus Nephritis.19 Such patients may resemble the subset 
of patients with DLDs but without clinically relevant renal disease in our 
population. 
 
These reports, together with our results, suggest that SLE-related 
complement abnormalities are a risk factor for DLDs. Clinically detectable 
renal involvement may only be an adjunctive risk factor, or a concomitant SLE 
manifestation, for a more aggressive ocular disease that is characterized by 
numerous, large, widely spread lesions. 
 
Our study found a peculiar distribution of DLDs throughout the posterior pole 
in SLE patients. Topographic analysis showed foveal spearing, with only a 
quarter of the 
DLDs found within the central ETDRS subfield. This ring-shaped distribution 
differs from the centripetal distribution usually found with typical age-related 
drusen,20 This suggests that drusen and DLDs may be due to different 
underlying mechanisms. Age-related drusen develop because Bruch’s 
membrane thickens due to lipid and protein accumulation.21 This aging 
process does not spare the center of the macula and frequently leads to 
subfoveal lesions. 
 
If deposition of blood-born complement factors constitutes the primary 
mechanism of DLD development, their disposition could be highly influenced 
by flow within the choriocapillaris.22 Filling of the choriocapillaris begins in the 
macula and progresses radially towards the periphery in a wavelike manner.23 
This centripetal blood flow pattern may be responsible for the peculiar 
perifoveal distribution of the lesions and the relative sparing of the central 
high-flow region. Further studies are needed to completely explain the 
distribution of DLDs. 
 
Subfoveal choroidal thickness was greater in our SLE patients than in 
controls, which differs from the findings of Altinkaynak et al.11 More than sixty 
percent of our SLE patients were receiving systemic corticosteroids at the 
time of the study. Drug-induced choroidal thickening, as it occurs in patients 
with central serous chorioretinopathy taking coricosteroids,24,25 seems unlikely 
in our cases since there was no significant difference in SCT between treated 
and untreated SLE patients. Considering the well-known relationship between 
choroidal thickness and systemic inflammatory conditions, a low grade, 
subclinical inflammation could be considered responsible for the choroidal 
thickening.26 Despite the theory that complement activation contributes to the 
formation of DLDs, we did not find a correlation between any of the ARA 
criteria (apart from the kidney involvement) or a history of complement 
depletion, and the presence of DLDs in our subjects. This may be due to the 
systemic indicators that we chose to evaluate the disease activity and level of 
complement depletion in our study. For example, clinical features including C3 
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and C4 depletion were graded in a binary manner only (i.e. present/absent), 
with no consideration for the duration of the changes, the nature of the 
measurement, or of the alteration itself. This may constitute a limitation of our 
study.  
 
Other limitations of the study include a limited sample size and the absence of 
immune-histochemical data related to the complement deposition found in the 
renal biopsies. The identification of complement factors in the glomeruli may 
strongly correlate with the presence of DLDs as suggested by recent 
studies.18 We also did not perform genetic studies in our patients, so we could 
not determine the presence of AMD-related polymorphisms27 that could be 
correlated with the development of DLDs. Finally, only those lesions located in 
the central area of the retina (ETDRS grid) were included as 30º SD-OCT 
scans were used for the analyses. Since wide-field OCT was not available at 
the time of this study, lesions outside the posterior pole could not be 
assessed. Involvement of the macula is of primary interest to clinicians, but 
analyses of the mid-peripheral retina could provide valuable and clinically 
meaningful information for both nephrologists and ophthalmologists. 
 
In conclusion, our findings offer a novel insight into the effects of SLE on the 
retina and choroid. Until a correlation between systemic SLE features and 
DLDs is identified, not only patients with renal involvement but all SLE 
patients should be considered at risk for DLDs. The correlation between SLE-
related DLDs and the development of complications such as choroidal 
neovascularization or RPE atrophy has not been established. In other 
conditions, it has been suggested that similar lesions may increase the 
chances of developing sight-threatening complications.28,29 Systematic 
screening of the fundus with non-invasive, high-resolution imaging techniques 
such as SD-OCT should be considered to detect DLDs in patient with SLE. 
Additional studies that focus on complement abnormalities and genetics in 
SLE patients are needed to confirm and expand upon our results. Additional 
data might determine if a correlation exists between worsening of DLDs and 
renal involvement, and if a link exists between SLE and AMD. 
 
 
Acknowledgments/Disclosure 
Founding Support: None 
Financial Disclosures: No financial disclosures. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Drusen-like deposits in Systemic Lupus Erythematosus 
 9 
References 
1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011; 
365(22):2110-21. 
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the 
classification of systemic lupus erythematosus. Arthritis Rheum 1982; 
25:1271-7.  
3. Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic 
lupus erythematosus: a review of the literature. Autoimmune Dis. 
2012;2012:290898. 
4. Ushiyama O, Ushiyama K, Koarada S, et al. Retinal disease in patients 
with systemic lupus erythematosus. Ann Rheum Dis. 2000; 59(9):705-
8.  
5. Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus 
retinopathy. Patterns, associations, and prognosis. Arthritis Rheum. 
1988; 31(9):1105-10. 
6. Baglio V, Gharbiya M, Balacco-Gabrieli C, et al. Choroidopathy in 
patients with systemic lupus erythematosus with or without 
nephropathy. J Nephrol. 2011;24(4):522-9.  
7. Kanagasingam Y, Bhuiyan A, Abràmoff MD, et al. Progress on retinal 
image analysis for age related macular degeneration. Prog Retin Eye 
Res. 2014;38:20-42.  
8. Yi K, Mujat M, Park BH, et al. Spectral domain optical coherence 
tomography for quantitative evaluation of drusen and associated 
structural changes in non-neovascular age-related macular 
degeneration. Br J Ophthalmol. 2009;93(2):176-81.  
9. Adhi M, Read SP, Liu JJ, et al. High-speed ultrahigh-resolution OCT of 
Bruch's membrane in membranoproliferative glomerulonephritis type 2. 
Ophthalmic Surg Lasers Imaging Retina. 2014;45(6):614-7.  
10. Lally DR, Baumal C. Subretinal drusenoid deposits associated with 
complement-mediated IgA nephropathy. JAMA Ophthalmol. 
2014;132(6):775-7.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Drusen-like deposits in Systemic Lupus Erythematosus 
 10 
11. Altinkaynak H, Duru N, Uysal BS, et al. Choroidal Thickness in Patients 
with Systemic Lupus Erythematosus Analyzed by Spectral-domain 
Optical Coherence Tomography. Ocul Immunol Inflamm. 2015:1-7.  
12. Hahn BH, McMahon M, Wilkinson A, et al. American College of 
Rheumatology Guidelines for Screening, Case Definition, Treatment 
and Management of Lupus Nephritis. Arthritis care & research. 
2012;64(6):797-808.  
13. Schlanitz FG, Ahlers C, Sacu S, et al. Performance of drusen detection 
by spectral-domain optical coherence tomography. Invest Ophthalmol 
Vis Sci. 2010;51(12):6715-21. 
14. D'souza Y, Short CD, McLeod D, Bonshek RE. Long-term follow-up of 
drusen-like lesions in patients with type II mesangiocapillary 
glomerulonephritis.Br J Ophthalmol. 2008;92(7):950-3.  
15. Duvall J, Tso MO. Cellular mechanisms of resolution of drusen after 
laser coagulation. An experimental study. Arch Ophthalmol. 
1985;103(5):694-703. 
16. Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of 
drusen associated with glomerulonephritis: implications for the role of 
complement activation in drusen biogenesis. Eye 2001;15(Pt 3):390-5. 
17. Savige J, Amos L, Ierino F, et al. Retinal disease in the C3 
glomerulopathies and the risk of impaired vision. Ophthalmic Genet. 
2016:1-8. 
18. Dalvin LA, Fervenza FC, Sethi S, Pulido JS. Shedding light on fundus 
drusen associated with membranoproliferative glomerulonephritis: 
breaking stereotypes of types I, II, and III. Retin Cases Brief Rep. 
2016;10(1):72-8. 
19. Ishizaki J, Saito K, Nawata M, et al. Low complements and high titre of 
anti-Sm antibody as predictors of histopathologically proven silent 
lupus nephritis without abnormal urinalysis in patients with systemic 
lupus erythematosus. Rheumatology 2015;54(3):405-12.  
20. Farsiu S, Chiu SJ, O'Connell RV, et al; Quantitative classification of 
eyes with and without intermediate age-related macular degeneration 
using optical coherence tomography. Ophthalmology. 2014;121(1):162-
72.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Drusen-like deposits in Systemic Lupus Erythematosus 
 11 
21. Bowes Rickman C, Farsiu S, Toth CA, Klingeborn M. Dry age-related 
macular degeneration: mechanisms, therapeutic targets, and imaging. 
Invest Ophthalmol Vis Sci. 2013;54(14):ORSF68-80. 
22. Hayreh SS. Vascular pattern of the choriocapillaris. Exp Eye Res. 
1974;19(1):101-4.  
23. Flower RW. Extraction of choriocapillaris hemodynamic data from ICG 
fluorescence angiograms. Invest Ophthalmol Vis Sci. 1993;34(9):2720-
9. 
24. Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: 
Recent findings and new physiopathology hypothesis. Prog Retin Eye 
Res. 2015;48:82-118.  
25. Yang L, Jonas JB, Wei W. Optical coherence tomography-assisted 
enhanced depth imaging of central serous chorioretinopathy. Invest 
Ophthalmol Vis Sci. 2013;54(7):4659-65.  
26. Ersan I, Kilic S, Arikan S, Kara S, Işik S, Gencer B, Ogretmen 
Z.Evaluation of Macular Ganglion Cell-inner Plexiform Layer and 
Choroid in Psoriasis Patients Using Enhanced Depth Imaging Spectral 
Domain Optical Coherence Tomography. Ocul Immunol Inflamm. 2016 
Mar 25:1-5. [Epub ahead of print] 
27. Hoffman JD, van Grinsven MJ, Li C, Brantley M Jr, McGrath J, Agarwal 
A, Scott WK, Schwartz SG, Kovach J, Pericak-Vance M, Sanchez CI, 
Haines JL. Genetic Association Analysis of Drusen Progression. Invest 
Ophthalmol Vis Sci. 2016;57(4):2225-31. 
28. Leys A, Vanrenterghem Y, Van Damme B, et al. Fundus changes in 
membranoproliferative glomerulonephritis type II. A fluorescein 
angiographic study of 23 patients. Graefes Arch Clin Exp Ophthalmol. 
1991;229(5):406-10.  
29. Leys A, Michielsen B, Leys M, Vanrenterghem Y, Missotten L, Van 
Damme B.Subretinal neovascular membranes associated with chronic 
membranoproliferative glomerulonephritis type II. Graefes Arch Clin 
Exp Ophthalmol.1990;228(6):499-504. 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Drusen-like deposits in Systemic Lupus Erythematosus 
 12 
Figure Legends 
Figure 1. Drusen-like deposits (DLDs) size assessment technique on 
spectral-domain optical coherence tomography (SD-OCT) scan.  
Measurement of DLD size is divided into two steps. First, the borders of the 
retinal pigment epithelium (RPE) detachment (black arrowheads), 
representing the deposits’ lateral boundaries, and Bruch’s Membrane (white 
arrowheads) were identified 
(Left). Following this, a linear segment parallel to Bruch’s membrane was 
drawn 
between the previously identified RPE borders using the Heyex Eye 
Explorer® linear caliper measurement tool (Right). 
Figure 2 Multimodal imaging set in a patient diagnosed with Systemic 
Lupus Erythematosus (SLE) showing Drusen-like deposits temporal to 
the fovea. 
In the fundus color pictures (Top-left), DLDs are visible as multiple yellowish 
lesions of different sizes affecting the temporal region of the posterior pole. 
The same area shows a grainy appearance on Blue Autofluorescence 
(Topmiddle) with the lesions appearing as multiple hypo-fluorescent grains 
when compared to the surrounding retina. A smaller number of hyper-
reflective dots corresponds to the DLDs on the blue reflectance image (Top 
Right). On the near infrared reflectance image (Bottom Left), a mix of 
hyper/hypo reflective changes are visible in the areas affected by DLDs. The 
horizontal Spectral 
Domain Optical Coherence tomography scan (Bottom Right), clearly shows 
the presence of multiple DLDs that wrinkle the overlying retinal pigment 
epithelium in the temporal region of the posterior pole. These DLDs spare the 
fovea. 
Figure 3. Systemic Lupus Erythematosus (SLE)-related Drusen-like 
deposits (DLDs) of different sizes as they appear on Spectral Domain 
Optical Coherence Tomography (SD-OCT) scans. 
An SD-OCT scan shows the presence of different sized DLDs throughout the 
posterior pole (Top Row) and some of the lesions are visible beneath the 
fovea. Subfoveal lesions are unusual since central macular involvement was 
found in only 25% of the subjects affected by DLDs. (Bottom Row) The SD-
OCT shows small (Left), medium (Middle) and large (Right) DLDs, which 
correspond to <50 µm, 50 to 100 µm, and ≥100 µm lesions according to the 
proposed classification. 
Figure 4. Drusen-like deposits (DLDs) distribution across the posterior 
pole in patients affected by Systemic Lupus Erythematosus (SLE). 
The percentage of eyes with DLDs in each quadrant is reported. Regions 
outside the fovea correspond to the intermediate and the external quadrants 
of the ETDRS grid, whereas the central region is represented by the foveal 
ETDRS sector. A ring shaped localization of the lesions is clearly visible along 
with partial foveal sparing. 
Figure 5. Multimodal Imaging set showing Drusen-like deposits (DLDs) 
affecting both eyes in a patient diagnosed with Systemic Lupus 
Erythematosus (SLE). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Drusen-like deposits in Systemic Lupus Erythematosus 
 13 
In the color fundus photos (Top/Third Row, left column), DLDs are seen as 
multiple yellowish lesions of different sizes spread across the posterior pole, 
but mainly located in the temporal region. DLDs appear hyper-autofluorescent 
on blue autofluorescence (Top/Third Row, Central column). A mix of 
hyper/hypo reflective granular changes are visible on blue reflectance 
(Top/Third row, right column) and near infrared reflectance (Second/Bottom 
row, left column). Spectral-domain optical coherence tomography (SD-OCT) 
scans encompass the fovea, whose location is represented by green arrows 
on near infrared reflectance Images, clearly show a sparing of the foveal 
region with the DLDs mainly located in the temporal region. Inferior scans 
performed along the black arrows, demonstrate several small DLDs (white 
arrowheads) that wrinkle the overlying retinal pigment epithelium, but are 
barely visible with the other imaging modalities (Second and Bottom row). 
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Table 1. Clinical Features of patients with systemic lupus 
erythematosus 
 
Age (years) * 42.43 ± 9.07  (19-55) 
Sex (M:F) 1:59  
 
Disease onset age (years)* 25.06 ± 8.68 (10-48) 
Disease Duration (years) 
*
 
17.48 ± 9.10 (1-33) 
 
ARA Criteria# 
 
  
1 – Malar Rash 50% (30/60) 
2 – Discoid Rash 18.33% (11/60) 
3 – Photosensitivity  51.66% (31/60) 
4 – Oral ulcers 5% (5/60) 
5 – Arthritis 58.33% (35/60) 
6 – Serositis 8.33% (5/60) 
7 – Renal disorder  50% (30/60) 
8 – Neurologic 
disorder 
5% (3/60) 
9 – Hematologic 
disorder 
56.66% (34/60) 
10 – ANA positivity 96.66% (58/60) 
11a – Anti DNA Ab 95% (57/60) 
11b – Anti ENA Ab 61.66% (37/60) 
 
C3# 85% (51/60) 
C4# 76.66% (46/60) 
 
Hydroxychloroquine# 88.33% (53/60) 
Cumulative Dose (g) * 728.09 ± 696.50  (0-2920) 
Corticosteroids#§ 63.33% (38/60) 
Immunosuppressive 
Drugs#§ 
60% (36/60) 
 
ARA=American Reumathologists Association; ANA= Anti-Nucleous Antibody 
* Mean ± SD (range) 
# Prevalence: % (number of subjects/n) 
§ Therapy at the time the study was performed 
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Table 2. Ocular findings in patients with systemic lupus erythematosus compared to age- 
and gender-matched controls 
 
 SLE patients  Controls P Value 
 
   
Subjects with DLDs 40% (24/60) 3.33% (2/60) p<0.0001 
 
   
Bilateral DLDs 28.33% (17/60) 0/60 p=0.0001 
 
   
Retinal pigment 
epitheliopathy 
5% (3/60) 0/60 p=0.242 
 
   
Subfoveal choroidal thickness 
(mean ± SD)  
362.7 ± 142.2 µm 296.5 ± 83.4 µm p=0.002 
SLE=Systemic Lupus Erythematosus;  DLDs=Drusen-like deposits 
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Table 3. Comparison between Drusen-Like Deposits’ features in Systemic Lupus Erythematosus patients 
with and without glomerulonephritis 
 
 SLE patients with 
renal involvement 
SLE patients without 
renal involvement 
P Value 
 
   
Subjects with DLDs#  12/30 12/30 1 
 
   
DLDs type*    
- Small Deposits 10/12 8/12 0.640 
- Medium Deposits 5/12 7/12 0.684 
- Large Deposits 8/12 2/12 0.036 
 
  
 
More than 3/5 quadrants involved*  7/12 1/12 0.009 
 
  
 
Number of DLDs/eye (median, 
range)* 
9.5 (6-125) 4.5 (1-11) 0.001 
 
   
Bilateral DLDs# 8/30 9/30 1 
Retinal pigment epitheliopathy# 0/30 3/30 0.237 
Choroidal thickness (mean ± SD) # 337.6  ± 93.2 µm 387.8  ± 176.4 µm 0.174 
 
   
SLE= Systemic Lupus Erythematosus; DLDs=Drusen Like Deposits 
# Statistics performed on the total SLE population (n=60) 
* Statistics performed on the subset of patients affected by DLDs (n=24) 
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A multimodal imaging study was conducted on a cohort of young patients affected by Systemic 
Lupus Erythematosus (SLE), with or without glomerulonephritis and healthy controls. Drusen-
like deposits (DLDs) were identified in a large percentage of SLE patients regardless the renal 
involvement. Spectral Domain Optical Coherence Tomography resulted the most suitable 
technique for the detection DLDs. The presence of DLDs in SLE patients may support the 
proposed relationship existing between complement disturbances and drusen formation. 
